PluriFRA:4DX 25 FCF Margin % is -2,736.81% as of Mar. 2026. GuruFocus rates FRA:4DX with a GF Score™ of 25/100 and a GF Value™ of €17.09. The stock has 6 warning signs investors should review. Among 960 Biotechnology companies, Pluri ranks worse than 84.48% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Pluri's Free Cash Flow for the
three
months ended in Mar. 2026 was €-3.94 Mil. Pluri's Revenue for the
three
months ended in Mar. 2026 was €0.14 Mil. Therefore, Pluri's FCF Margin % for the quarter that ended in Mar. 2026 was -2,736.81%.
The historical rank and industry rank for Pluri's FCF Margin % or its related term are showing as below:
FRA:4DX'
s FCF Margin % Range Over the Past 10 Years
Min: -115821.74 Med: -11886.89 Max: -712.05
Current: -2010.68
During the past 13 years, the highest FCF Margin % of Pluri was -712.05%. The lowest was -115821.74%. And the median was -11886.89%.
FRA:4DX's FCF Margin % is ranked worse than 84.48% of 960
companies
in the Biotechnology industry
Industry Median: -85.21
vs FRA:4DX: -2010.68
Pluri FCF Margin % Related Terms
Pluri FCF Margin % Historical Data
* Premium members only.
The historical data trend for Pluri's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:4DX vs VTGN, PTN, CLRB: FCF Margin % Comparison
For the Biotechnology subindustry, Pluri's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pluri FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pluri's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Pluri's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pluri (FRA:4DX) has a FCF Margin % of -2,736.81% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Pluri and its competitors. According to the industry distribution chart, Pluri ranks #811 out of 960 companies in the Biotechnology industry, placing it in the top 84.5%.
Is Pluri's FCF Margin % too high?
Pluri's current FCF Margin % is -2,736.81%. Based on the distribution chart, Pluri ranks #811 out of 960 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Pluri has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Pluri's FCF Margin % compare to VTGN and PTN?
According to the Biotechnology industry distribution chart, Pluri ranks #811 out of 960 companies for FCF Margin %. This places Pluri in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Pluri and its competitors. Pluri's current FCF Margin % is -2,736.81%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pluri stock overvalued right now?
Pluri (FRA:4DX) has a current FCF Margin % of -2,736.81%. The stock's GF Value™ is €17.09, compared to a current price of €5.60 — trading 67.2% below its estimated fair value. The current FCF Margin % is -2,736.81%. Pluri's overall GF Score™ is 25/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Pluri (FRA:4DX), the current FCF Margin % is -2,736.81% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pluri (FRA:4DX) Overvalued in 2026?
Based on GuruFocus' analysis, Pluri stock appears to be undervalued.
The current stock price of €5.60 is trading 67.2% below its estimated GF Value™ of €17.09.
Key valuation signals for FRA:4DX:
FCF Margin %: -2,736.81%
GF Value™: €17.09 vs. price of €5.60 (67.2% below fair value)
No single metric tells the full story. See the FRA:4DX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
25GF Score
Get the complete analysis for FRA:4DX
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4DX has been successfully added to your 
